

**PCR-/NAT *C. trachomatis* & GO  
 (RV 530) April 2011**



**Tabelle 1:** Probenzusammensetzung und erwartetes Ergebnis.  
*Sample composition and expected results.*

	<i>Erwartet / expected</i>		<i>Probenzusammensetzung / Sample composition</i>
1115301	∅ / ∅	64	<i>Neisseria meningitidis</i>
1115302	∅ / +	63	<i>Neisseria gonorrhoeae</i> (~ 1x10 <sup>4</sup> CFU/mL)
1115303	+ / ∅	61	<i>Chlamydia trachomatis</i> (~ 1x10 <sup>3</sup> IFU/mL)
1115304	∅ / ∅	64	<i>Neisseria cinerea</i>

**Tabelle 2:** Häufigkeit der Mitteilung verschiedener Befunde.  
*Absolute numbers of reported individual results.*

<i>n = 141</i>	<i>Probennummer (Sample no.)</i>				<i>Inhibition</i>				
	1115301	1115302	1115303	1115304	1115301	1115302	1115303	1115304	
<b>Befund Result</b>									
<b>Positiv CT</b>	1	0	136	1	n.d.	0	0	0	0
<b>Positiv CT &amp; GO</b>	0	2	3	1	nein / no	140	141	141	140
<b>Positiv GO</b>	13	137	0	29	ja / yes	1	0	0	1
<b>Negativ</b>	126	2	2	109					
<b>Fraglich /questionable</b>	1	0	0	1					

**Tabelle 3:** Häufigkeit richtig positiver und richtig negativer NAT-Befunde bei Anwenden verschiedener Methoden. *Absolute numbers and relative frequency of reported true positive and true negative results among various NAT methods.*

<b>NAT-Methode</b> [Code] (total number *)	<b>NAT richtig positiv</b> <i>True positive results</i>			<b>NAT richtig negativ</b> <i>True negative results</i>		
	<b>Absolut</b> <i>Absolute</i>	<b>Relativ</b> <i>Relative</i>	<b>%</b>	<b>Absolut</b> <i>Absolute</i>	<b>Relativ</b> <i>Relative</i>	<b>%</b>
GenProbe CT/NG [20] (n = 2)	3	3 / 4	75	4	4 / 4	100
LightMix CT/NG [21] (n = 11)	22	22 / 22	100	22	22 / 22	100
Roche COBAS TaqMan [22] (n = 24)	47	47 / 48	98	48	48 / 48	100
COBAS Amplicor [23] (n = 17)	34	34 / 34	100	34	34 / 34	100
BD ProbeTec [24] (n = 26)	52	52 / 52	100	18	18 / 52	35
Artus CT [25] (n = 4)	8	8 / 8	100	8	8 / 8	100
Abbott RealTime CT/NG [26] (n = 30)	60	60 / 60	100	60	60 / 60	100
Other commercial tests [27] (n = 29)	56	56 / 58	97	48	48 / 56 <sup>§</sup>	86
In house PCR assay [28] (n = 23)	45	45 / 46	98	38	38 / 46	83
Andere / k.A. / other [29] (n = 3)	6	6 / 6	100	4	4 / 6	67

Legend for Table 3:

- \* Durch Mehrfachnennung oder fehlende Angabe kann die absolute Zahl der Ergebnisse (Tab. 2) von der Anzahl der Teilnehmer abweichen.  
 Due to reporting results of multiple assay systems or missing specifications, the effective numbers are not correlating with the number of participants.
- § Due to reporting questionable results, the number of true results (denominator in the "relative" column) have been reduced.

**Tabelle 4: Häufigkeit richtig positiver und richtig negativer NAT-Befunde bei Anwendern verschiedener Methoden. Anmerkung: in dieser Tabelle sind nur die Ergebnisse für *Chlamydia trachomatis* dargestellt.**  
 Absolute numbers and relative frequency of reported true positive and true negative results among various NAT methods

**Note: only the *C. trachomatis*-specific results are depicted in this table.**

NAT-Methode ( <b>nur CT</b> ) [Code] (total number *)	NAT richtig positiv <i>True positive results</i>			NAT richtig negativ <i>True negative results</i>		
	Absolut <i>Absolute</i>	Relativ <i>Relative</i>	%	Absolut <i>Absolute</i>	Relativ <i>Relative</i>	%
GenProbe CT/NG [20] (n = 2)	1	1 / 2	50	6	6 / 6	100
LightMix CT/NG [21] (n = 11)	11	11 / 11	100	33	33 / 33	100
Roche COBAS TaqMan [22] (n = 24)	24	24 / 24	100	72	72 / 72	100
COBAS Amplicor [23] (n = 17)	17	17 / 17	100	51	51 / 51	100
BD ProbeTec [24] (n = 26)	26	26 / 26	100	78	78 / 78	100
Artus CT [25] (n = 4)	4	4 / 4	100	12	12 / 12	100
Abbott RealTime CT/NG [26] (n = 30)	30	30 / 30	100	90	90 / 90	100
Other commercial tests [27] (n = 29)	28	28 / 29	97	84	84 / 87	97
<i>In house</i> PCR assay [28] (n = 23)	22	22 / 23	96	67	67 / 69	97
Andere / k.A. / other [29] (n = 3)	3	3 / 3	100	9	9 / 9	100

\* Durch Mehrfachnennung oder fehlende Angabe kann die absolute Zahl der Ergebnisse (Tab. 2) von der Anzahl der Teilnehmer abweichen.  
 Due to reporting results of multiple assay systems or missing specifications, the effective numbers are not correlating with the number of participants.

**Tabelle 5: Häufigkeit richtig positiver und richtig negativer NAT-Befunde bei Anwendern verschiedener Methoden. Anmerkung: in dieser Tabelle sind nur die Ergebnisse für *Neisseria gonorrhoeae* dargestellt.**

*Note: only the N. gonorrhoeae-specific results are depicted in this table.*

NAT-Methode ( <b>nur GO</b> ) [Code] (total number *)	NAT richtig positiv <i>True positive results</i>			NAT richtig negativ <i>True negative results</i>		
	Absolut <i>Absolute</i>	Relativ <i>Relative</i>	%	Absolut <i>Absolute</i>	Relativ <i>Relative</i>	%
GenProbe CT/NG [20] (n = 2)	2	2 / 2	100	6	6 / 6	100
LightMix CT/NG [21] (n = 11)	11	11 / 11	100	33	33 / 33	100
Roche COBAS TaqMan [22] (n = 24)	23	23 / 24	96	72	72 / 72	100
COBAS AmpliCor [23] (n = 17)	17	17 / 17	100	51	51 / 51	100
BD ProbeTec [24] (n = 26)	26	26 / 26	100	44	44 / 78	56
Artus CT [25] (n = 4)	4	4 / 4	100	12	12 / 12	100
Abbott RealTime CT/NG [26] (n = 30)	30	30 / 30	100	90	90 / 90	100
Other commercial tests [27] (n = 29)	28	28 / 29	97	79	79 / 85 <sup>§</sup>	93
<i>In house</i> PCR assay [28] (n = 23)	23	23 / 23	100	63	63 / 69	91
Andere / k.A. / other [29] (n = 3)	3	3 / 3	100	7	7 / 9	78

\* Durch Mehrfachnennung oder fehlende Angabe kann die absolute Zahl der Ergebnisse (Tab. 2) von der Anzahl der Teilnehmer abweichen.  
*Due to reporting results of multiple assay systems or missing specifications, the effective numbers are not correlating with the number of participants.*

§ Due to reporting questionable results, the number of true results (denominator in the "relative" column) have been reduced.

**Tabelle 6: Falsch-positive und falsch-negative NAT-Befunde nach Methode**  
*False-positive and -negative NAT results with commercial or in-house assays*

NAT-Methode NAT method	Positive samples		Negative samples	
	GO positive 1115302	CT positive 1115303	1115301	1115304
GenProbe CT/NG [20] (n = 2)	-	1/2 CT-	-	-
LightMix CT/NG [21] (n = 11)	-	-	-	-
Roche COBAS TaqMan [22] (n = 24)	1/24 GO-	-	-	-
COBAS AmpliCor [23] (n = 17)	-	-	-	-
BD ProbeTec [24] (n = 26)	-	1/26 GO+	7/26 GO+	26/26 GO+
Artus CT [25] (n = 4)	-	-	-	-
Abbott RealTime CT/NG [26] (n = 30)	-	-	-	-
Other commercial tests [27] (n = 29)	1/29 CT+ 1/29 GO-	1/29 GO+ 1/29 CT-	3/29 GO+	2/29 GO+ 2/29 CT+
<i>In house</i> PCR assay [28] (n = 23)	1/23 CT+	1/23 GO+ 1/23 CT-	3/23 GO+ 1/23 CT+	2/23 GO+
Andere / k.A. / other [29] (n = 3)	-	-	1/3 GO+	1/3 GO+